MATRIXLABS

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 97876.4 lacs for year ending on 31-MAR-2008 against Rs. 74950.6 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. (29835.7) lacs for the year ending on 31-MAR-2008 against Rs. 9961.3 lacs for the year ending on 31-MAR-2007.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 176158.9 lacs for year ending on 31-MAR-2008 against Rs. 164802.7 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. (45692.7) lacs for the year ending on 31-MAR-2008 against Rs. 7631 lacs for the year ending on 31-MAR-2007.

Matrix Laboratories Limited has informed the Exchange vide its letter dated May 12, 2008 that "Mylan Inc., USA, (Mylan) the ultimate holding company of Matrix Laboratories Limited (Matrix) has reported today (12th May, in the US), the unaudited interim consolidated financials of Mylan for the quarter ended 31st March, 2008 under US GAAP reporting, which inter alia included the following unaudited details of Matrix: Segment profitability (on a US GAAP basis) of $3,617,000 for the three months ended 31 March, 2008. Please note that financial results of Matrix for the quarter ended / year ended 3

Matrix Laboratories Limited has informed the Exchange vide its letter dated May 09, 2008 that "Mylan Inc., USA, (Mylan) the ultimate holding company of Matrix Laboratories Limited (Matrix) has reported today (8th May, in the U.S.), the unaudited interim consolidated financials of Mylan for the quarter ended 31st March, 2008 under US GAAP reporting, which inter alia included the following unaudited details of Matrix: Revenues for the three months ended 31 March, 2008 (on a US GAAP basis) of US $103 million, including third party sales of US$ 87.6 million. Please note that financial results of M

Matrix Laboratories Limited has informed the Exchange that : "The Company will publish audited financial results for the financial year ending 31st March, 2008 within three months i.e. by 30th June, 2008, and hence we would not be publishing the unaudited financial results for the last quarter ended 31st March, 2008."

Matrix Laboratories Limited has informed the Exchange that: Mr Jagdish Viswanath Dore has joined Matrix Laboratories Limited as Chief Executive officer of the Company effective April 21, 2008.

Matrix Laboratories Limited has informed the Exchange regarding a press release dated February 28, 2008, titled "Matrix to Pursue Strategic Alternatives including Potential Divestiture of Docpharma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Martrix_PR_28022008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that: "Mr. Rajiv Malik, the incumbent Managing Director and Chief Executive Officer of Matrix Laboratories Limited will be relocated to U.S in connection with his employment by the parent company, Mylan Inc. He will be succeeded by Mr. Jagadish Dore. The effective dates for relocation/ date of joining will be finalised subsequently". Further the Company has also submitted to the exchange a copy of press release in this regard dated February 27, 2008, titled "Matrix Laboratories Announces Appointment of Jagdish Dore' as CEO". A copy of the p

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 45354 lacs for quarter ending on 31-DEC-2007 against Rs. 39525.2 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 1543.2 lacs for the quarter ending on 31-DEC-2007 against Rs. (87.4) lacs for the quarter ending on 31-DEC-2006.

Matrix Laboratories Limited has informed the Exchange regarding a press release dated January 24, 2008, titled "Acquisition of Residual Holding in MChem Group of Companies, China". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_PR_25012008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated December 04, 2007 titled "Matrix announces tentative FDA Approval under PEPFAR for Tenofovir Disoproxil Fumarate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/MATRIX_PR_05122007.zip target=NEW> For more details click here.</a>

News Verification : The media had reports that Mylan may come out with a delisting offer for Matrix and are looking at buying the residual stake. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated,"As on date Mylan Laboratories Inc.,USA is neither contemplating to buy residual stake nor delist the securities of the Company from the Stock Exchanges. Hen

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on October 30, 2007 considered and approved the following items :- 1) Appointment of Prof. P V Indiresan as an Additional Director on the Board of the Company with effect from October 30, 2007; 2) Appointment of Prof. P. V. Indiresan as the member of the Audit Committee.

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 42799.3 lacs for half year ending on 30-SEP-2007 against Rs. 33665.5 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 3943.2 lacs for the half year ending on 30-SEP-2007 against Rs. 3858.1 lacs for the half year ending on 30-SEP-2006.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 82342.6 lacs for half year ending on 30-SEP-2007 against Rs. 81533.8 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 1695.9 lacs for the half year ending on 30-SEP-2007 against Rs. 4966.1 lacs for the half year ending on 30-SEP-2006.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 37641 lacs for quarter ending on 30-SEP-2007 against Rs. 37317.8 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. (992.5) lacs for the quarter ending on 30-SEP-2007 against Rs. 1585.9 lacs for the quarter ending on 30-SEP-2006.

Matrix Laboratories Limited has informed the Exchange that "The Compensation Committee of the Board on 22nd September, 2007, by circulation, have allotted 45,300 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid-up share capital of the Company has increased to Rs. 30,89,70,726/-".

Matrix Laboratories Limited has informed the Exchange vide its letter dated September 19, 2007 that the address of the Registrar & Share Transfer Agent of the Company Viz., Venture Capital & Corporate Investments Limited is changed with immediate effect and the new address is as under: Venture Capital and Corporate Investments Limited, Unit: Matrix Laboratories Limited, 12-10-167, Bharat Nagar, Hyderabad-500 018, Phone no(s): 040-23818475/76, Fax no: 040-23868024.

Matrix Laboratories Limited has submitted to the Exchange a copy of the Abstract & Memorandum of Interest, in terms of Section 302 of the Companies Act, 1956, pertaining to variation in terms of remuneration of Mr Rajiv Malik, Managing Director & Chief Executive Officer. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_misc_19092007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated August 24, 2007 titled "Agreement to acquire residual holding in MChem Group of Companies, China". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_PR_240807.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on July 16, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_AGM_17082007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that "The Compensation Committee of the Board on 3rd August, 2007, by circulation, have allotted 51,206 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid-up share capital of the Company has increased to Rs. 30,88,80,126/-".

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on July 25, 2007 considered and approved the following items: (a) Appointment of Mr. Sandip Choudhury as Chief Financial Officer of the Company, effective July 09, 2007. (b) Resignation of Mr.N.Anjaneyulu as Company Secretary and Compliance Officer effective from the close of business hours of July 31, 2007; and (d) Appointment of Mrs. V. Sheela as Company Secretary and Compliance Officer of the Company, effective from August 01, 2007.

Matrix Laboratories Limited has informed the Exchange regarding the press release, titled "Matrix Records Net Sales of Rs.4,470 Million And Net Profit of Rs.269 Million For Q1 FY 08". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_26072007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 44701.6 lacs for quarter ending on 30-JUN-2007 against Rs. 44216 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 2688.4 lacs for the quarter ending on 30-JUN-2007 against Rs. 3380.2 lacs for the quarter ending on 30-JUN-2006.

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 20610.1 lacs for quarter ending on 30-JUN-2007 against Rs. 19412.1 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 2579.2 lacs for the quarter ending on 30-JUN-2007 against Rs. 2897.2 lacs for the quarter ending on 30-JUN-2006.

Matrix Laboratories Limited has informed the Exchange that all resolutions placed at the Annual General Meeting of the Company held on July 16, 2007, in terms of the Notice dated May 23, 2007, have been unanimously passed by the Members of the Company. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_AGM.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has submitted to the Exchange a copy of the notice of the Annual General Meeting of the Members of the Company to be held on July 16, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_AGM_29062007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that: "The Compensation Committee of the Board on 14th June, 2007, by circulation, have allotted 2,80,770 Equity Shares of Rs.2/- each under ESOP-2004 Scheme. Consequent to the above allotment, the paid-up share capital of the Company has increased to Rs.30,87,77,150/-".

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on May 23, 2007, considered and approved the following items: (1) To convene and conduct Annual General Meeting of the Company on July 16, 2007.(2) Closure of Register of Members and Share Transfer Books from July 11, 2007 to July 16, 2007 for the purpose of AGM.

Matrix Laboratories Limited has informed the Exchange regarding a press release dated May 23, 2007, titled "Matrix Records Net Sales of Rs.16,480 Million And Net Profit of Rs.763 Million For FY 07". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/MatrixLab_PR240507.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated May 09, 2007, titled "Matrix signs agreement with Clinton Foundation for ARV Drugs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_PR_090507.zip target=NEW> For more details click here.</a>

The Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.

Matrix Laboratories Limited has informed the Exchange that "The Compensation Committee of the Board on 29th March, 2007 by circulation, have allotted 78,420 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid-up share capital of the Company has increased to Rs. 30,82,15,610/-."

Matrix Laboratories Limited has informed the Exchange that "the Company has exclusively designated the following e-mail ID for redressal of investor's complaints - investorrelations@matrixlabsindia.com".

Matrix Laboratories Limited has submitted to the Exchange a copy of the Notice of Declaration of Results of Postal Ballot in respect of the Resolution for Amendment to Articles of Association of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_resPB_010307.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has submitted to the Exchange a copy of the Abstract of Memorandum of Interest pertaining to appointment of Mr. Rajiv Malik as Managing Director & Chief Executive Officer. A copy of the same shall be available on the NSE website (http://www.nseindia. com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_23022007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that "The Compensation Committee of the Board on 17th February, 2007 by circulation, have allotted 63,175 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid-up share capital of the Company has increased to Rs. 30,80,58,770/-."

Matrix Laboratories Limited has informed the Exchange on January 31, 2007, that: "The Board of Directors of the Company at their meeting held on even date considered and approved the following items : Agreement dated January 31, 2007 with Mr. Rajiv Malik pursuant to which Mr. Malik will continue as the Managing Director and acting Chief Executive Officer of the Company on deputation from Mylan Laboratories Inc. (USA), for whom Mr. Malik serves as Head of Global Technical Operations. An abstract of the terms and conditions of Mr. Rajiv Malik's agreement with Matrix would be forwarded to the Mem

Matrix Laboratories Limited has informed the Exchange regarding a press release, dated January 31, 2007, titled "Matrix records net sales of Rs. 3,953 million in Q3FY07." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_press_010207.zip target=NEW> For more details click here.</a>

News Verification : The media had reports on January 30, 2007 that Matrix Laboratories Limited may announce a buyback. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "The company confirms that as on date it is not contemplating a buy back of its securities."

Matrix Laboratories Limited has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the following resolution is proposed to be passed, as special resolution by means of Postal Ballot: Amendment to Articles of Association of the Company under Section 31 of the Companies Act, 1956. The Board of Directors of the Company have appointed Mr. P. Jagannatham, Partner of M/s. Puttaparthi Jagannatham & Co., Company Secretaries, as the Scrutinizer (the "Scrutinizer") for conducting this postal b

(ii) Resignation of Directors (iii) Appointment of Additional Director (iv) Reconstitution of Committees. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_OBM_09012007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that: "The Board of Directors of the Company at their meeting held today i.e. 8th January, 2007 :- i) Noted that the transactions under the Share Purchase Agreement (SPA) between MP Laboratories (Mauritius) Ltd, a wholly owned subsidiary of Mylan Laboratories Inc. U.S.A. ('Acquirers'), and Mr. Prasad Nimmagadda, Prasad Nimmagadda-HUF, G2 Corporate Services Limited, India Newbridge Investments Limited, India Newbridge Partners FDI Limited, India Newbridge Coinvestment Limited, Maxwell (Mauritius) Pte Limited and Spandana Foundation ('the Sel

Matrix Laboratories Limited has informed the Exchange regarding a press release dated January 08, 2007, titled "Mylan Laboratories Completes Matrix Laboratories Transaction". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_Press_090107.zip target=NEW> For more details click here.</a>

DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Post Offer Public Announcements which has been simultaneously published on December 27, 2006 by DSP Merrill Lynch Limited as Manager to the Offer on behalf of MP Laboratories (Mauritius) Ltd. ("Acquirer"), and Mylan Laboratories Inc. ("Persons Acting in concert" / "PAC") to the shareholders of Matrix Laboratories Limited. A copy of the public announcement shall be available on the NSE website (http://www.nseindia. com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a hr

DSP Merrill Lynch Limited has submitted to the Exchange a copy of the revision to the Public Announcements dated August 29,2006, October 20,2006 and November 18,2006. This Public Announcement has been simultaneously published on November 30, 2006 by DSP Merrill Lynch Limited as Manager to the Offer on behalf of MP Laboratories (Mauritius) Ltd. ("Acquirer"), and Mylan Laboratories Inc. ("Mylan" / "PAC") to the shareholders of Matrix. A copy of the public announcement shall be available on the NSE website (http://www.nseindia. com) under: Corporates > Latest Announcements and on the Extranet Ser

DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Corrigendum to the Public Announcement made on August 29,2006, which has been made by DSP Merill Lynch Limited as Manager to the Offer on behalf of MP Laboratories (Mauritius) Ltd. (hereinafter referred to as "Acquirer"), and Mylan Laboratories Inc. (hereinafter referred to as "Mylan" / "Person acting in concert"/"PAC") to the shareholders of Matrix. The original and revised schedule of major activities of the offer is as follows : (1) Date of opening of the offer (a) October 20, 2006 (Original) (b) November 22, 2006 (Revis

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings at the AGM of the Company held on September 25, 2006. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_AGM_02112006.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated October 31,2006, titled �Matrix records net sales of Rs.3732 million and net profit of Rs.159 million for Q2FY07�. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_31102006.zip target=NEW> For more details click here.</a>